Simon Cleall

2.7k total citations · 1 hit paper
17 papers, 2.0k citations indexed

About

Simon Cleall is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Statistics and Probability. According to data from OpenAlex, Simon Cleall has authored 17 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Surgery and 3 papers in Statistics and Probability. Recurrent topics in Simon Cleall's work include Diabetes Management and Research (10 papers), Diabetes Treatment and Management (8 papers) and Diabetes Management and Education (3 papers). Simon Cleall is often cited by papers focused on Diabetes Management and Research (10 papers), Diabetes Treatment and Management (8 papers) and Diabetes Management and Education (3 papers). Simon Cleall collaborates with scholars based in United Kingdom, Spain and United States. Simon Cleall's co-authors include Peter Albers, D. Roychowdhury, Pierre Kerbrat, Peter Wersäll, Alexander Knuth, Luigi Dogliotti, Pedro Sánchez‐Rovira, Hans von der Maase, T. Oliver and Malcolm J. Moore and has published in prestigious journals such as Journal of Clinical Oncology, Diabetes Care and Diabetes Obesity and Metabolism.

In The Last Decade

Simon Cleall

17 papers receiving 2.0k citations

Hit Papers

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastin... 2000 2026 2008 2017 2000 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
    2000 1.7k citations Hans von der Maase, Steen Werner Hansen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Simon Cleall United Kingdom 10 1.5k 604 392 344 297 17 2.0k
D. Roychowdhury United States 11 1.5k 1.0× 799 1.3× 367 0.9× 435 1.3× 33 0.1× 17 2.1k
R. Sylvester Belgium 21 686 0.5× 637 1.1× 214 0.5× 976 2.8× 189 0.6× 54 1.9k
Jeremy Crew United Kingdom 20 841 0.6× 284 0.5× 609 1.6× 393 1.1× 55 0.2× 54 1.7k
Brigitte Duclos France 20 531 0.4× 508 0.8× 627 1.6× 769 2.2× 79 0.3× 52 1.6k
Ho Kyung Seo South Korea 22 1.1k 0.8× 515 0.9× 500 1.3× 749 2.2× 24 0.1× 148 2.1k
Hayakazu Nakazawa Japan 20 561 0.4× 698 1.2× 339 0.9× 477 1.4× 22 0.1× 64 1.7k
S. Huan Canada 16 383 0.3× 439 0.7× 160 0.4× 334 1.0× 73 0.2× 36 1.0k
Michiyuki Usami Japan 21 406 0.3× 187 0.3× 268 0.7× 962 2.8× 182 0.6× 89 1.3k
Enzo Maria Ruggeri Italy 22 354 0.2× 681 1.1× 274 0.7× 535 1.6× 39 0.1× 103 1.4k
F. H. Dexeus United States 11 840 0.6× 359 0.6× 181 0.5× 295 0.9× 16 0.1× 14 1.1k

Countries citing papers authored by Simon Cleall

Since Specialization
Citations

This map shows the geographic impact of Simon Cleall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Cleall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Cleall more than expected).

Fields of papers citing papers by Simon Cleall

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Cleall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Cleall. The network helps show where Simon Cleall may publish in the future.

Co-authorship network of co-authors of Simon Cleall

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Cleall. A scholar is included among the top collaborators of Simon Cleall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Cleall. Simon Cleall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Maase, Hans von der, Steen Werner Hansen, J.T. Roberts, et al.. (2023). Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. Journal of Clinical Oncology. 41(23). 3881–3890. 19 indexed citations
2.
Naik, Himanshu, Yuan Zhao, Fiona Forrestal, et al.. (2021). Population Pharmacokinetics of Vixotrigine in Healthy Volunteers and Subjects with Trigeminal Neuralgia, Painful Lumbosacral Radiculopathy and Erythromelalgia. European Journal of Drug Metabolism and Pharmacokinetics. 46(3). 395–404. 5 indexed citations
3.
Gross, Jorge Luiz, et al.. (2016). Efficacy and safety of a premixed versus a basal-plus insulin regimen as intensification for type 2 diabetes by timing of the main meal. Current Medical Research and Opinion. 32(6). 1109–1116. 2 indexed citations
4.
5.
Diamant, Michaëla, Michael A. Nauck, Rimma M. Shaginian, et al.. (2014). Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes. Diabetes Care. 37(10). 2763–2773. 169 indexed citations
6.
7.
Moreno, Luis, et al.. (2014). Impact of “Conversation Map™” tools on understanding of diabetes by Spanish patients with type 2 diabetes mellitus: A randomized, comparative study. Endocrinología y Nutrición (English Edition). 61(10). 505–515. 10 indexed citations
8.
Tinahones, Francisco J., Jorge Luiz Gross, Adriana Onaca, Simon Cleall, & Ángel Rodríguez. (2014). Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial. Diabetes Obesity and Metabolism. 16(10). 963–970. 33 indexed citations
9.
10.
Oğuz, Aytekin, et al.. (2013). Clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study. Current Medical Research and Opinion. 29(8). 911–920. 25 indexed citations
11.
12.
13.
Koivisto, Veikko A, Simon Cleall, A. E. Pontiroli, & Dario Giugliano. (2011). Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal‐bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open‐label trial. Diabetes Obesity and Metabolism. 13(12). 1149–1157. 11 indexed citations
14.
Eastell, Richard, Peyman Hadji, Jordi Farrerons, et al.. (2006). Comparison of 3 sequential treatment regimens of teriparatide: Final results from the EUROFORS study. University of Southern Denmark Research Portal (University of Southern Denmark). 3 indexed citations
15.
Stallard, Nigel, John Whitehead, & Simon Cleall. (2005). Decision-making in a phase II clinical trial: a new approach combining Bayesian and frequentist concepts. Pharmaceutical Statistics. 4(2). 119–128. 25 indexed citations
16.
17.
Maase, Hans von der, Steen Werner Hansen, J.T. Roberts, et al.. (2000). Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. Journal of Clinical Oncology. 18(17). 3068–3077. 1678 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Roychowdhury Breakdown of academic impact, for papers by R. Sylvester Breakdown of academic impact, for papers by Jeremy Crew Breakdown of academic impact, for papers by Brigitte Duclos Breakdown of academic impact, for papers by Ho Kyung Seo Breakdown of academic impact, for papers by Hayakazu Nakazawa Breakdown of academic impact, for papers by S. Huan Breakdown of academic impact, for papers by Michiyuki Usami Breakdown of academic impact, for papers by Enzo Maria Ruggeri Breakdown of academic impact, for papers by F. H. Dexeus
Rankless by CCL
2026